COVID-19 Impact on Chronic Myeloid Leukemia Patients

Arbore, Dana Raluca; Galdean, Simona Maria; Dima, Delia; Rus, Ioana; Kegyes, David; Ababei, Raluca Geanina; Dragancea, Daniela; Tomai, Radu Andrei; Tomuleasa, Ciprian

doi:10.3390/jpm12111886

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While most clinicians associate the presence of BCR-ABL fusion gene with chronic myeloid leukemia (CML), about 10% of healthy control patients express at least some measurable copies in their peripheral blood [ 97 ]. Prior work relating COVID-19 to CML concisely summarizes the role of the gene in upregulating fusion transcripts and proteins, ultimately intensifying the presence and activity of tyrosine kinase within the body [ 98 ]. Recent extensive investigation of tyrosine kinase has revealed its direct association in vasculopathy as well as its antihypertensive properties from its interactions with endothelial receptors [ 99 ].…”

Section: Discussionmentioning

confidence: 99%

“…Prior work relating COVID-19 to CML concisely summarizes the role of the gene in upregulating fusion transcripts and proteins, ultimately intensifying the presence and activity of tyrosine kinase within the body [98]. Recent extensive investigation of tyrosine kinase has revealed its direct association in vasculopathy as well as its antihypertensive properties from its interactions with endothelial receptors [99].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19

Kartchner,

McCoy,

Dubey

et al. 2023

Biology

View full text Add to dashboard Cite

Multiple studies have reported new or exacerbated persistent or resistant hypertension in patients previously infected with COVID-19. We used literature-based discovery to identify and prioritize multi-scalar explanatory biology that relates resistant hypertension to COVID-19. Cross-domain text mining of 33+ million PubMed articles within a comprehensive knowledge graph was performed using SemNet 2.0. Unsupervised rank aggregation determined which concepts were most relevant utilizing the normalized HeteSim score. A series of simulations identified concepts directly related to COVID-19 and resistant hypertension or connected via one of three renin–angiotensin–aldosterone system hub nodes (mineralocorticoid receptor, epithelial sodium channel, angiotensin I receptor). The top-ranking concepts relating COVID-19 to resistant hypertension included: cGMP-dependent protein kinase II, MAP3K1, haspin, ral guanine nucleotide exchange factor, N-(3-Oxododecanoyl)-L-homoserine lactone, aspartic endopeptidases, metabotropic glutamate receptors, choline-phosphate cytidylyltransferase, protein tyrosine phosphatase, tat genes, MAP3K10, uridine kinase, dicer enzyme, CMD1B, USP17L2, FLNA, exportin 5, somatotropin releasing hormone, beta-melanocyte stimulating hormone, pegylated leptin, beta-lipoprotein, corticotropin, growth hormone-releasing peptide 2, pro-opiomelanocortin, alpha-melanocyte stimulating hormone, prolactin, thyroid hormone, poly-beta-hydroxybutyrate depolymerase, CR 1392, BCR-ABL fusion gene, high density lipoprotein sphingomyelin, pregnancy-associated murine protein 1, recQ4 helicase, immunoglobulin heavy chain variable domain, aglycotransferrin, host cell factor C1, ATP6V0D1, imipramine demethylase, TRIM40, H3C2 gene, COL1A1+COL1A2 gene, QARS gene, VPS54, TPM2, MPST, EXOSC2, ribosomal protein S10, TAP-144, gonadotropins, human gonadotropin releasing hormone 1, beta-lipotropin, octreotide, salmon calcitonin, des-n-octanoyl ghrelin, liraglutide, gastrins. Concepts were mapped to six physiological themes: altered endocrine function, 23.1%; inflammation or cytokine storm, 21.3%; lipid metabolism and atherosclerosis, 17.6%; sympathetic input to blood pressure regulation, 16.7%; altered entry of COVID-19 virus, 14.8%; and unknown, 6.5%.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19

Kartchner,

McCoy,

Dubey

et al. 2023

Biology

View full text Add to dashboard Cite

show abstract

Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era

Bao

Gao

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

Chronic Myeloid Leukemia in Bulgaria in the New Millennium: Identification of Directions for Improvement in Management and Outcomes Reporting

Shivarov,

Grigorova,

Nedeva

et al. 2024

Hemato

View full text Add to dashboard Cite

Background: In the last two decades, tyrosine kinase inhibitors (TKIs) and advances in molecular diagnostics have revolutionized management and long-term clinical outcomes in chronic myeloid leukemia (CML). Real-world data from different countries allow for the identification of country-specific issues in the clinical management and development of specific plans for improvement. Here, we aimed to analyze the trend in overall survival in Bulgarian CML patients since 2000. Methods: We retrieved publicly available Bulgarian CML data from several sources such as the Bulgarian National Cancer Registry, Bulgarian National Statistical Institute, and National Health Insurance Fund since 2000. We used the retrieved data of a total of 1513 Bulgarian CML patients to describe the trends in overall survival (OS), conditional overall survival, life expectancy, and life years lost over five time periods. We also described the trends in healthcare expenditures for TKIs and CML patients’ coverage with TKIs since 2014. Results: In both uni- and multivariate models, we found a constant increase in OS over the three 5-year periods until 2014. The period 2015–2019 was not associated with an additional increase in OS. Identical dynamics in the improvement in life expectancy (LE) and in life years lost (LYLs) was observed. Additionally, conditional 5-year survival did not improve during 2015–2019 in comparison to 2010–2014. Population-level data did not show consistent changes in the documented number of deaths due to CML since 2013. The period after 2013 is marked by a constant increase in the annual expenditures for TKIs, reaching to about 2.0 EUR/capita. The number of patients who received at least one TKI also increased during that period. Conclusions: After the initial significant improvement in the clinical outcomes for Bulgarian CML patients until 2014, subsequent periods did not bring further benefit in spite of the improved coverage with second- and third-line TKIs. Multiple factors may contribute to these suboptimal outcomes. Therefore, one can propose several additional measures at the country level, which could lead to additional improvement in the OS of Bulgarian CML patients.

show abstract

COVID-19 Impact on Chronic Myeloid Leukemia Patients

Cited by 3 publications

References 38 publications

Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19

Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19

Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era

Chronic Myeloid Leukemia in Bulgaria in the New Millennium: Identification of Directions for Improvement in Management and Outcomes Reporting

Contact Info

Product

Resources

About